Slotnik Capital LLC Boosts Position in Catalent, Inc. (NYSE:CTLT)

Slotnik Capital LLC lifted its stake in Catalent, Inc. (NYSE:CTLT) by 45.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 283,500 shares of the company’s stock after purchasing an additional 88,000 shares during the quarter. Catalent comprises about 5.7% of Slotnik Capital LLC’s holdings, making the stock its 9th biggest position. Slotnik Capital LLC’s holdings in Catalent were worth $17,172,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Millennium Management LLC grew its holdings in Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after buying an additional 2,299,784 shares in the last quarter. Bank of Montreal Can boosted its holdings in Catalent by 181.5% during the 3rd quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock valued at $109,388,000 after acquiring an additional 1,169,044 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Catalent by 166.5% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company’s stock valued at $83,733,000 after acquiring an additional 863,624 shares during the period. ING Groep NV boosted its holdings in Catalent by 162.5% during the 3rd quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock valued at $68,475,000 after acquiring an additional 699,851 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in Catalent during the 3rd quarter valued at $39,082,000.

Catalent Trading Up 0.2 %

CTLT opened at $61.12 on Friday. Catalent, Inc. has a 52 week low of $36.74 and a 52 week high of $61.50. The business has a fifty day simple moving average of $59.90 and a 200-day simple moving average of $58.47. The firm has a market cap of $11.09 billion, a P/E ratio of -27.04, a P/E/G ratio of 2.42 and a beta of 1.16. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the business earned ($0.10) earnings per share. The firm’s quarterly revenue was up 4.2% on a year-over-year basis. On average, equities analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on CTLT. William Blair restated a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Robert W. Baird restated a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, StockNews.com lowered Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $63.40.

Insider Buying and Selling at Catalent

In other news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the transaction, the director now owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock worth $305,931 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.